Home›Olopatadine Hydrochloride And Mometasone Furoate

Olopatadine Hydrochloride And Mometasone Furoate

Also known as: Ryaltris

Route: Nasal

Check Olopatadine Hydrochloride And Mometasone Furoate Interactions →

3 interactions on record

Olopatadine Hydrochloride And Mometasone Furoate has 3 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Alcohol, Central Nervous System Depressants, Mao Inhibitors. Patients taking Olopatadine Hydrochloride And Mometasone Furoate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Moderate: 3

Moderate (3)

Olopatadine Hydrochloride And Mometasone Furoate + Alcohol— Concurrent use with alcohol may cause somnolence and impairment of central nervous system performance.
Olopatadine Hydrochloride And Mometasone Furoate + Central Nervous System Depressants— Concurrent use with CNS depressants should be avoided due to risk of somnolence and impairment of CNS performance.
Olopatadine Hydrochloride And Mometasone Furoate + Mao Inhibitors— Strong CYP3A4 inhibitors may inhibit metabolism of mometasone furoate, increasing plasma concentration and risk of adver…

Olopatadine Hydrochloride And Mometasone Furoate + Alcohol🟡Moderate

Concurrent use with alcohol may cause somnolence and impairment of central nervous system performance.

Olopatadine Hydrochloride And Mometasone Furoate + Central Nervous System Depressants🟡Moderate

Concurrent use with CNS depressants should be avoided due to risk of somnolence and impairment of CNS performance.

Olopatadine Hydrochloride And Mometasone Furoate + Mao Inhibitors🟡Moderate

Strong CYP3A4 inhibitors may inhibit metabolism of mometasone furoate, increasing plasma concentration and risk of adverse reactions.

Contraindications

4 CONTRAINDICATIONS RYALTRIS is contraindicated in patients with known hypersensitivity to any ingredients of RYALTRIS. Hypersensitivity reactions, including wheezing, has occurred after nasal administration of mometasone furoate [see Warnings and Precautions ( 5.4 )]. Patients with known hypersensitivity to any ingredients of RYALTRIS, including mometasone furoate. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are no available data on RYALTRIS or mometasone furoate use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Postmarketing experience with antihistamines, with similar mechanism of action to olopatadine, have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. However, there are no published human data specific to olopatadine. Animal reproduction studies have not been conducted with RYALTRIS. However, animal reproduction studies are available for olopatadine hydrochloride and mometasone furoate. Oral administration of olopatadine hydrochloride to pregnant rats and rabbits caused a decrease in the number of live fetuses at maternal doses approximately 120 and 1600 times the maximum recommended human daily intranasal dose (MRHDID) on a mg/m 2 basis, respectively (see Data) . In animal reproduction studies with pregnant mice, rats, or rabbits, mometasone furoate caused increased fetal malformations and decreased fetal survival and growth following administration of doses that produced exposures approximately 1 to 16 times the MRHDID on a mcg/m 2 or AUC basis (see Data) . However, experience with oral corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroid exposure than humans. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data No reproductive toxicology studies were conducted with RYALTRIS; however, studies are available for olopatadine hydrochloride and mometasone furoate, as described below. Olopatadine hydr

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.